GroPep finally closes Biotech Australia chapter
Tuesday, 07 October, 2003
GroPep (ASX:GRO) has closed the book on its acquisition of Biotech Australia with the receipt of AUD$3.6 million final payment for the Roseville site.
CFO Tony Mitchell said the terms of last year's $10.1 million sale to property developers Macquarie Real Estate Equity Fund No 1 and an investment company of Denham Construction were set at about two-thirds payable up front with the remainder payable now.
He said that GroPep had effectively exited from the Biotech Australia acquisition, retaining some equipment and one project from the company.
At the time of writing, GroPep's share price had risen 14 per cent to $0.80.
Novel antibiotic activates 'suicide' mechanism in superbug
Researchers have discovered a new class of antibiotic that selectively targets Neisseria...
Modifications in the placenta linked to psychiatric disorders
Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...
ADHD may be linked with an increased risk of dementia
An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...
